by TractManager | May 31, 2018 | Emerging Technology Report
Xeljanz is an oral Janus kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). Xeljanz is the first oral therapy to be FDA-approved for the treatment of moderately to severely active UC.If you have a...
by TractManager | May 31, 2018 | Health Technology Assessment
Health Problem: A patent foramen ovale (PFO) is a persistent, flap-like opening between the atrial septum primum and secundum. In 25% of adults, the foramen ovale remains open, or patent. The presence of a PFO has no therapeutic consequence in otherwise healthy...
by TractManager | May 31, 2018 | Health Technology Assessment
Health Problem: Tears and/or tendinopathy of the rotator cuff (RC) can occur due to degeneration, trauma, repetitive overhead motions, and/or excessive loading. Current treatment strategies generally do not restore the native functional and structural properties of...
by TractManager | May 25, 2018 | Health Technology Assessment
Health Problem: More than 17 million surgeries were performed in hospitals or ambulatory surgical centers associated with hospitals in 2014 in the United States. Up to 80% of surgical patients have postoperative pain, or acute pain after surgery. Use of adjunct...
by TractManager | May 23, 2018 | Precision Therapy Assessment
Health Problem: Prader-Willi syndrome (PWS) is a genetic disorder that is highly variable and can affect multiple body systems; there is an associated pattern of physical findings with significant cognitive, neurologic, endocrine, and behavioral abnormalities. Studies...
Recent Comments